HONG KONG, Nov. 2, 2020 /PRNewswire/ -- Amgen Asia Holding Limited has announced the appointment of My Linh Kha as Vice President & General Manager, Japan Asia-Pacific (JAPAC). Ms. Kha has been Vice President & General Manager of Amgen China since February 2019 and will continue in this role until a successor is appointed. In this role, she led Amgen's strategic collaboration with BeiGene to expand the company's oncology presence in China.
Ms. Kha succeeds Penny Wan, who will retire at the end of this year to ensure a smooth transition.
Since its early beginnings in 2014, Amgen JAPAC has grown from a fledgling region with one affiliate and a small regional head quarters to a formidable organization of over 2,000 staff. In the past six years under Ms. Wan's leadership, JAPAC has grown its commercial business and its presence having executed approximately 80 product launches across 14 markets and eight stand-alone affiliates.
Led by a headquarters and clinical trial hub in Hong Kong, Amgen JAPAC now serves over one million patients across the region. Its R&D efforts and strategic collaborations are truly reflective of the value of Amgen's products for patients and for society at large.
"Through ongoing efforts such as national partnerships to research and promote healthy aging and preventative healthcare initiatives, we are confident that we will be able to build a robust and complete medicine portfolio to address these needs, especially across bone health, cardiovascular and oncology," said Ms. Kha.
The JAPAC region is home to the world's largest aging population, and has significant unmet medical needs.With over 60 percent of the world's elderly population expected to reside in Asia-Pacific by 2030, Amgen is addressing the rising healthcare burdens in this fastest-aging region.
"I am excited to be building upon Penny's work in JAPAC by maintaining and extending this focus within the region," added Ms. Kha.
Ms. Kha has more than 20 years of experience in the pharma/ biotech industry and a strong track record in delivering outstanding business results. She has worked in multiple geographies, including Asia Pacific, Latin America, the Middle East and Europe.
 Voice of Asia, Third Edition, September 2017, Deloitte
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Related Links :